Corvus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

• Corvus Pharmaceuticals Inc CRVS.OQ reported a quarterly adjusted loss of 60 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of five analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -14 cents to -10 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Corvus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 60 cents​.

• The company reported a quarterly loss of $40.22 million.

• Corvus Pharmaceuticals Inc shares had risen by 81.1% this quarter and gained 443.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is 10.00

This summary was machine generated from LSEG data November 12 at 11:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)